The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates the effects of aromatic hydrocarbons, such as 2, 3, 7, ; the prototypical response is induction of drug-metabolizing enzymes.
Introduction
Exogenous aromatic hydrocarbons bind to and activate the aryl hydrocarbon receptor (AHR). These ligands include 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a halogenated aromatic hydrocarbon, and 3-methylcholanthrene (MC), a non-halogenated polycyclic aromatic hydrocarbon (PAH) [1] . The AHR is the chemical sensor and mediator of the majority of the toxic effects of aromatic hydrocarbons. The importance of the AHR in the effects of aromatic hydrocarbons was exemplified by observations that Ahr-null mice do not show the characteristic toxicities associated with TCDD exposure and the vast majority of TCDD-induced hepatic transcriptional changes are lost in Ahr-null mice [2] .
The AHR is a cytosolic, ligand-activated transcription factor. Ligand binding elicits activation of the AHR complex and translocation to the nucleus, followed by heterodimerization of the liganded AHR with its nuclear partner, the AHR nuclear translocator (ARNT). The AHR•ARNT heterodimer binds to specific regulatory elements on DNA, termed aromatic hydrocarbon response elements (AHREs) contained within the regulatory regions of aromatic hydrocarbon-responsive genes. The best-documented aromatic hydrocarbon-responsive genes encode drug-metabolizing enzymes (DMEs). Particularly well-studied are the members of the CYP1 family, CYP1A1, 1A2 and 1B1 [3] , and several phase II conjugating enzymes [4] .
The AHR is ubiquitously expressed, but the levels of AHR mRNA and protein vary between tissues. Highest mRNA expression is observed in lung, liver, kidney, placenta and thymus, while lower expression is observed in the heart [5] . Thymus and liver are highly sensitive to effects of TCDD [6] , which might be influenced by the relatively high level of the AHR in these tissues. Since the level of AHR varies in a tissue-selective manner, AHR levels are likely regulated by endogenous factors.
Hormones are potential endogenous regulators of AHR expression levels and AHR function. AHR regulation by pituitary hormones was observed by Burke et al. [7] . They observed that hepatic CYP1A-catalyzed enzymatic reactions induced by MC were attenuated in hypophysectomized (HYPX) rats. We previously observed that HYPX significantly reduced hepatic AHR protein and ligand-binding in male rats [8] . It is not apparent which pituitarydependent factors that were depleted with HYPX are responsible for the reduced hepatic AHR protein and ligand-binding.
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A c c e p t e d M a n u s c r i p t 4 We set out to identify plausible pituitary-dependent factors involved in regulation of hepatic AHR levels. Adrenal glucocorticoids are pituitary-dependent hormones that have been shown to modulate responses to aromatic hydrocarbons. For example, physiological stress in rats involves an elevation of plasma corticosterone (CORT), the predominant rodent glucocorticoid.
In rats under stress, there was enhanced hepatic ethoxyresorufin-O-deethylation (EROD) activity following PAH administration, a measure of CYP1A1 activity [9] . In cultured rodent cells, glucocorticoids potentiate CYP1A1 inducibility by aromatic hydrocarbons [10] [11] [12] .
Glucocorticoid potentiation of PAH-induced CYP1A1 was also observed in rats [13, 14] , whereas glucocorticoids alone had no effect on CYP1A1 protein level or EROD activity. There is a functional glucocorticoid response element (GRE) in intron I of the CYP1A1 gene [15] , which contributes in part to the glucocorticoid-potentiated PAH-induced CYP1A1 activity. The GRE in intron I is conserved between mouse, rat and human CYP1A1 genes. However, this glucocorticoid-mediated potentiation was observed only in rodent hepatoma cells/hepatocytes and in rat liver, while induction of CYP1A1 protein [16] and EROD activity [17] by MC was inhibited by glucocorticoids in human hepatocytes. The disparity between the human and rodent responses indicates that the presence of the GRE in intron I does not alone confer the potentiation effect of glucocorticoids on CYP1A1 induction by PAHs. Most recently, a bidirectional cross-talk between the AHR and the glucocorticoid receptor (GR) has been observed in HO23 human ovarian granulosa cells, in which PAHs enhance glucocorticoid responsiveness and glucocorticoids inhibit PAH responsiveness [18] . This recent paper concludes with the suggestion that in vivo animal studies will be needed to investigate the physiological significance of this in vitro crosstalk, an issue addressed in the present study.
In addition to the evidence above that implicates glucocorticoids in the response to aromatic hydrocarbons, glucocorticoids are also putative regulators of the level of hepatic AHR expression. Glucocorticoids increased AHR levels and enhanced expression of AHR target genes in H4IIE rat hepatoma cells [12, 19] . Glucocorticoids repressed AHR mRNA levels in human hepatocytes [17] and in rat mammary fibroblasts [20] , indicating a possible cell-specific response. In HepG2 human hepatoma cells, dexamethasone (DEX) reduced AHR mRNA levels [18, 21] and TCDD-induced EROD activity, with no effect on AHR protein [21] . Once again, these studies suggest that the positive effect of glucocorticoids on the AHR system occurs in rodent, but not human, liver. Recently we found that DEX increased the level of AHR mRNA,
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A c c e p t e d M a n u s c r i p t 5 protein and ligand-binding in Hepa-1 mouse hepatoma cells. A functional impact of the altered level of AHR was observed as DEX pre-treatment enhanced induction of an AHR-activated luciferase reporter by TCDD and MC in Hepa-1 cells [22] . With respect to in vivo evidence regarding the glucocorticoid effect on AHR expression, Abbott et al. [23] showed that hydrocortisone increased AHR mRNA and protein in the embryonic mouse palate. A previous study in adrenalectomized (ADX) rats one week after surgery showed no alteration of AHR ligand-binding as measured by isoelectric focusing [24] . The evidence demonstrating a role for glucocorticoids in the positive modulation of the AHR system in cell culture has not been experimentally verified in the adult rodent liver.
Our objective was to study whether removal of the endogenous source of glucocorticoids by ADX, combined with exogenous glucocorticoid treatment, affects the level of AHR in rat liver. Our hypothesis is that ADX rats have lower AHR protein and ligand-binding, as observed in liver of HYPX rats. Our second hypothesis is that glucocorticoid treatment in ADX rats restores the level of AHR protein and ligand-binding to normal levels. In addition to the study of the effects of ADX and glucocorticoids on the level of the AHR, we investigated the functional impact of ADX on the AHR-dependent adaptive response to MC. We hypothesize that a lower level of AHR will result in a reduced adaptive response to MC.
This study documents the in vivo contribution of adrenal-dependent endogenous factors to the regulation of the level of AHR mRNA, protein and ligand-binding in rodent liver. We also provide a novel example of how altered AHR levels affect the response to MC in vivo. This finding provides mechanistic insight into the in vivo functional consequences of altered hepatic AHR protein levels. Glucocorticoid levels fluctuate under different physiological and pathophysiological conditions, and are altered via pharmacological intervention. Knowing the conditions under which AHR levels are altered and whether this alteration results in functional consequences will provide a better understanding of the factors that contribute to the sensitivity to aromatic hydrocarbon exposure and the associated toxicities. For all studies, the liver was processed for RNA and cytosol preparation as described previously [8] . Briefly, each liver was perfused in situ with 50 ml of ice-cold HEGD buffer (25 
Immunoblot analysis.
Cytosolic protein (25-40 g) from each rat liver was resolved by SDS-polyacrylamide gel electrophoresis [28] and transferred to nitrocellulose membrane (Hybond-ECL, GE Healthcare Bio-Sciences) for AHR or ARNT detection. Antibody conditions for AHR immunoblotting were optimized previously [22] and confirmed for rat liver cytosol.
The anti-AHR antibody was used at a 1:20,000 dilution in TNT (20 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween-20) containing 5% skim milk powder with thimerasol, followed by incubation with a donkey anti-rabbit Ig-horseradish peroxidase conjugate at a 1:5,000 dilution in TNT containing 5% skim milk powder with thimerasol. The anti-ARNT antibody was used at a 1:2,000 (acute and subacute) or 1:3,000 (time course) dilution in TNT containing 5% skim milk powder with thimerasol, followed by incubation with a donkey anti-rabbit Ig-horseradish peroxidase conjugate at a 1:1,000 (acute and subacute) or 1:2,000 (time course) dilution in TNT containing 5% skim milk powder with thimerasol. ECL detection was then performed and the blots were exposed to Bioflex imaging film. Films were processed using a SRX-101A medical film processor (Konica Minolta, Wayne, NJ). 
Analysis of AHR, ARNT, TAT and -actin mRNA levels by semiquantitative RT-PCR. Total
RNA was isolated from liver tissue by the acid guanidinium thiocyanate-phenol-chloroform extraction method [29] using Tri-Reagent. RNA samples were then treated with 20 U DNase I at M a n u s c r i p t 9 37°C for 25 min to remove genomic DNA contamination. RNA yield and purity were assessed by determining the A 260 /A 280 ratio (> 1.7), and RNA integrity was assessed by comparing the relative intensities of the 28S and 18S rRNA bands as visualized on an ethidium bromide-stained agarose gel. RT-PCR was performed according to optimized conditions for annealing temperature, cycle number and cDNA input. The RT step was carried out as described previously [30] . Briefly, total RNA (1 g) was incubated with oligo d(T) 15 PCR buffer containing 20 mM Tris, 50 mM KCl and 3 mM MgCl 2 . PCR products were separated on 6% non-denaturing polyacrylamide gels. Gels were stained with Vistra Green and fluorescence was detected using a STORM 860 blue fluorescence scanner (Molecular Dynamics, Sunnyvale, CA). Relative quantitation was performed using IPLabGel software. AHR, ARNT and TAT signals were normalized to the internal reference standard, -actin. PCR cycling conditions (input cDNA, cycle number) were optimized to yield product within the exponential range of amplification for multiplex PCR. Table 2 . Cycling conditions were: initial cycle of 10 min at 95°C, followed by 40 cycles at 95°C for 15 s, 64°C for 1 min. A vehicle-treated SHAM sample was used as the calibrator sample and -actin mRNA was used as the endogenous control for each sample measured. Using the relative standard curve method according to Applied Biosystems, the quantity of target and -actin mRNA was interpolated using the determined Ct value for each sample and the standard curve plotting Ct vs. log RNA input. The CYP1B1 mRNA level for each sample was then normalized to -actin mRNA, and the fold difference for each sample was expressed relative to the normalized calibrator sample. The mean fold difference for each treatment group was expressed as a percentage of the vehicle-treated SHAM group.
Analysis of ARNT, TAT, CYP1B1 and -actin
Forward primers were manually designed so that they spanned an intron-exon boundary and reverse primers were designed using amplicon size specifications and forward primer sequence using Primer3 software [31] . The possibility of secondary structure formation was M a n u s c r i p t 12
Results

A single dose of DEX induces hepatic ARNT and TAT mRNA in SHAM and ADX rats
The levels of AHR, ARNT and TAT mRNAs were assessed by RT-PCR in ADX rats treated with one dose of DEX, 6 h before euthanasia (acute) or with a daily dose of DEX for seven consecutive days (subacute) (Fig. 1) . The level of AHR mRNA was unchanged by ADX or by DEX in either the acute or subacute protocol. While ARNT mRNA was unchanged in the subacute protocol, expression of the established glucocorticoid-inducible gene TAT also was unchanged. To assess the effect of DEX on gene expression under conditions in which TAT was induced, the acute protocol was used, where 2-fold TAT induction was observed at 6 h after DEX treatment. Under these conditions, the level of ARNT mRNA was significantly induced by 3 to 4-fold at 6 h post-dosing in both SHAM and ADX rats. ADX did not alter ARNT or TAT mRNA levels following either the acute or subacute protocol.
Hepatic AHR protein is decreased in ADX rats four days after surgery
AHR protein was measured in hepatic cytosol from SHAM and ADX rats treated with either vehicle or DEX by immunoblotting using a rabbit polyclonal antibody generated against the N-terminal region of the mouse AHR protein that has cross-reactivity to the rat protein.
Representative protein samples from each treatment group are shown in Fig. 2A , 
ADX and DEX do not affect ARNT protein level
Given the 3-to 4-fold induction of ARNT mRNA by DEX at 6 h post-dosing in the acute protocol, we measured the level of ARNT protein in hepatic cytosol from SHAM and ADX rats A c c e p t e d M a n u s c r i p t 13 treated with either vehicle or DEX (Fig. 3) . ARNT protein was measured in hepatic cytosol by immunoblotting using a rabbit polyclonal antibody generated against the C-terminal region of the human ARNT protein that has cross-reactivity to the rat protein. weeks after ADX, there was no effect of ADX or DEX on ARNT protein in the subacute protocol. Since ARNT is a nuclear protein that redistributes to the cytosol during subcellular fractionation of liver under basal conditions, it is important to point out that the measurements of ARNT protein in whole liver homogenate yielded similar results to liver cytosol (data not shown).
Hepatic AHR ligand-binding is decreased in vehicle-treated ADX rats four days after surgery
The level of TCDD binding sites was determined using a HAP assay. (Fig. 4) . This level of TCDD binding sites corresponds to reported values measured by HAP assay in rat liver cytosol of 20-140 fmol/mg protein [27, 33, 34] . In the acute study, the number of TCDD binding sites was reduced in vehicle-treated ADX rats relative to SHAM. In DEX-treated ADX rats, the number of TCDD binding sites was also reduced relative to SHAM, but did not achieve statistical significance. In the subacute study, the level of TCDD binding sites was similar to the findings for the concentration of AHR protein, in that there was no effect of ADX or DEX.
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The marked induction of ARNT mRNA by DEX occurs rapidly with no apparent change in ARNT protein levels
To assess the time course of ARNT mRNA induction by DEX (acute study) and whether there was a change in the level of ARNT protein at a time point before or after the 6 h measurement previously employed, intact rats received a single dose of DEX (1.5 mg/kg) followed by euthanasia at 3, 6, 12 or 27 h. Levels of ARNT and TAT mRNA were measured using real-time RT-PCR and the results are shown in Fig. 5 . Corresponding to what was previously observed in the acute study, ARNT mRNA is significantly induced 8.7-fold by DEX treatment at 6 h post-dosing, and a 7.1-fold induction also was observed at 3 h post-dosing; induction was not sustained 12 or 27 h post-dosing. With respect to TAT mRNA, maximal 8.7-fold induction by DEX was seen at 6 h post-dosing, which corresponds to previous published reports [35, 36] and confirms glucocorticoid responsiveness.
The level of AHR ( 
The induction of hepatic CYP1B1 mRNA by MC is reduced in ADX rats
ADX and SHAM rats were treated with a single MC dose (20 mg/kg) by gavage at 4 days after surgery to assess whether the response to an aromatic hydrocarbon was altered, given the depleted level of hepatic AHR protein following ADX. As a measure of the AHR-dependent adaptive response to MC, the level of CYP1B1 mRNA was measured using real-time RT-PCR and the results are shown in Fig. 8 . The level of hepatic CYP1B1 mRNA was induced 23.9-fold and 5.5-fold by MC in SHAM and ADX rats, respectively, relative to the surgery-matched, vehicle-treated control groups. The level of MC-induced hepatic CYP1B1 mRNA following ADX was 50% less than the level of MC-induced hepatic CYP1B1 mRNA in SHAM rats.
M a n u s c r i p t
Discussion
In our current study, we showed that by removing the adrenal glands, the endogenous source of glucocorticoids and other adrenal-dependent factors, the level of rat hepatic AHR protein was reduced four days after surgery. By administering a single acute dose of DEX, a synthetic glucocorticoid with a longer half-life than CORT, we demonstrated that exogenous glucocorticoid treatment could not alone reverse this AHR protein depletion. While the level of [19, 21, 22] . The nature of the interaction between these pathways in the whole animal had not yet been characterized. The evidence provided by our study suggests that:
(1) the adrenal status of rats affects the level of the hepatic AHR protein acutely following surgery, (2) the adaptive response to MC is affected by adrenal status and AHR levels, but (3) acute activation of the GR by exogenous DEX treatment is not sufficient to overcome the loss of adrenal-dependent factors involved in the maintenance of AHR levels.
Our findings, of reduced hepatic AHR protein levels and reduced induction of CYP1B1 mRNA in ADX rats, may provide an explanation for previous studies of PAH responsiveness.
Nebert and Gelboin [37] reported that MC-induced aryl hydrocarbon hydroxylase activity (a measure of CYP1A function) was significantly decreased in liver from ADX and HYPX rats, yet the nature of this difference in enzyme activity was not apparent. MC-induced metabolism of benzo[a]pyrene, a PAH that binds to and activates the AHR [1] , was 52% lower in ADX rats compared to MC-treated intact rats [38] . These two previous studies demonstrated that ADX shortly after mRNA induction with a one-hour lag time [36] . Our results suggest that direct glucocorticoid activation of the GR and subsequent transcriptional activation via direct DNA binding, as is the mechanism for TAT induction [39] , cannot account for the decreased hepatic AHR protein levels caused by ADX. It is more likely that other early endocrine perturbations caused by ADX, such as changes in insulin or growth hormone [40, 41] , or other GR molecular mechanisms, such as protein-protein interactions [39] , contribute to the effect of ADX on AHR protein levels.
Given that AHR mRNA levels remained unchanged following ADX, we showed that hepatic AHR protein depletion in ADX rats was not mechanistically related to transcriptional regulation of the AHR gene. However, we do not yet know the mechanism for ADX-dependent AHR protein depletion. The AHR protein is stabilized by components of the cytosolic protein complex in which it resides [42, 43] and AHR protein turnover is mediated by ubiquitindependent proteasomal degradation [44] . These are both possible avenues for mechanistic investigation of the observed ligand-independent regulation of AHR protein. Since AHR protein depletion was only observed at the earlier time point after ADX, the mechanism could be related to early perturbations of various adrenal-dependent factors that are compensated for over a longer post-surgical recovery. For these reasons, differences in DEX responsiveness between our M a n u s c r i p t 17 acute and subacute studies may relate to both differences in the dosing regimen and the time allowed for recovery from ADX.
We report here that when the level of the hepatic AHR is depleted following ADX, the response to MC treatment, as measured by hepatic CYP1B1 mRNA, is reduced. While there is a body of evidence regarding the effects of AHR ligands on the level of AHR expression in rodents, the net effect of changes to the magnitude of the response to aromatic hydrocarbons is not clearly understood because of the on-going presence of the ligand [30, 45, 46] . Our novel finding demonstrates a relationship between receptor levels and the response to aromatic hydrocarbons in vivo. While studying HYPX rats, our laboratory previously observed that the significant reduction of AHR protein and ligand-binding in HYPX rats did not correspond to a change in CYP1A1 inducibility [8] . In cell culture, it has been demonstrated repeatedly that the level of AHR expression can modulate sensitivity to aromatic hydrocarbons. For example, leukocytes express low basal levels of AHR. Sensitivity to the inhibitory effects of TCDD on these immunocompetent cells was directly related to a marked increase in AHR expression and function observed during leukocyte activation [47] . Taken together, these studies suggest that the target gene selected can be important in determining the impact of altered AHR levels on the response to aromatic hydrocarbon treatment.
Another finding of our study is that the level of hepatic ARNT mRNA was dramatically induced in vivo at early time points following a single dose of DEX in intact, SHAM and ADX rats. This observation is in line with supplemental data from a microarray analysis of liver showing that the level of ARNT mRNA was induced following methylprednisolone infusion, although only measured in ADX rats [48] . Given that induction of ARNT protein by DEX was not apparent in our study, it remains unclear whether the induction of ARNT mRNA alters ARNT function or the response to aromatic hydrocarbons or hypoxia. In order to determine the mechanism of the induction of ARNT mRNA and whether this translates to a change in ARNT protein using various doses of glucocorticoids and time points, additional studies in cell culture will be required. Teleologically, it would not be surprising if ARNT protein expression was under tight regulatory control, such as that by microRNA inhibition of translation, given that this gene is essential for survival [49] . This type of regulatory control could explain the apparent disconnect between the observed levels of ARNT mRNA and protein.
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While the regulation of the AHR by physiological and xenobiotic agents has been reported [50] , the evidence to support alteration of hepatic ARNT expression by endogenous or exogenous factors is minimal. Abbott et al. [51] showed that the level of ARNT mRNA expression increases developmentally in the embryonic mouse palate and that this effect can be suppressed by exposure to TCDD or hydrocortisone. The loss of ARNT has also been implicated in human pancreatic islet dysfunction associated with diabetes [52] . A recent paper
showed that the level of human ARNT protein decreased with increasing glucose concentrations and increased with reduced calcium flux in MIN6 cultured pancreatic islet cells [53] . The elevation of mouse ARNT mRNA by the hepatotoxin pyrazole was recently demonstrated [54] .
We conducted a preliminary analysis of the rat ARNT gene and identified two putative GREs within the first 10 kb of the transcription start site (data not shown). Our novel findings with respect to the regulation of ARNT mRNA by DEX in rat liver form the basis for continuing studies on the mechanism of ARNT mRNA regulation by glucocorticoids.
In conclusion, we have demonstrated that: (1) A c c e p t e d M a n u s c r i p t ________________________________________________________________________________________________________________ a The TAT primer sequences were originally designed based on the mouse cDNA sequence. The underlined and bolded bases were changed to match the rat cDNA sequence. A c c e p t e d M a n u s c r i p t 
